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ABSTRACT
Angiogenesis is very important in cancer growth and metastasis. Basic fibroblast growth
factor (bFGF) as one of the most important angiogenesis factors is an attractive target for cancer
vaccine. Due to low immunogenicity, it cannot stimulate an effective immune response. Theoretically,
pseudomonas exotoxin (PE) as a potent immunogenic carrier protein when fused to low
immunogenic antigens such as bFGF significantly increased immunogenicity of it. In this study, we
tried to molecular cloning and expression of bFGF conjugated with immunodominant domains of
pseudomonas exotoxin. The coding sequence of fusion protein composed of bFGF linked to PE
domains 1b and 2 using EAAAK poly linker. The KDEL sequence was also used in C-terminal
coding sequence. It was synthesized and expressed using recombinant DNA technology in the
bacterial expression system. Expression of recombinant protein verified using SDS-PAGE and
western blot analyses. Finally, it purified using Ni-affinity chromatography. The band close to 37
kDa in SDS-PAGE and western blot analyses was aligned completely to designed sequence.
Purified recombinant protein also showed as a clear single band near to 37 kDa.
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INTRODUCTION
Angiogenesis is formation of new blood
vessels and is fundamental mechanism in
numerous physiological and pathological
processes such as embryonic development, wound
healing and tumor metastasis 1,2. Basic fibroblast
growth factor (bFGF) and vascular endothelial
growth factor (VEGF) are potent angiogenic factors
that induce tumor growth 3. Theoretically, inhibition
of angiogenic factors can inhibit tumor metastasis.
Targeted therapies involve production of
components such as monoclonal antibodies4.
Today, a humanized anti-VEGF monoclonal
antibody ( Avastin) has been approved by the FDA
for treatment of colorectal cancer5. More studies
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showed that prolonged use of this drug may be
lead to drug resistance6. Detailed investigations
indicated that this resistance created by bFGF
effects on endothelial cells 7. Moreover, bFGF is
one of the most important regulators of human
embryonic stem cell (hESC) 8. Thus, it can be used
as a good target for cancer therapy. The bFGF has
155 amino acids length and has a molecular weight
(MW) of 17.2 kDa 9. Due to low immunogenicity and
short half-life, it cannot stimulate an effective
immune response 10. Several approaches have
been developed to potentiate immune response to
low immunogenic antigens such as adjuvant and
potent antigens as a carrier 11. The PE domains 1b
and 2 are one of the potent antigen carrier which
could significantly increase immunogenicity of low
immunogenic antigens 12. Moreover, PE when fused
to a weak tumor antigens stimulate a protective
cytotoxic T lymphocytes (CTL) response to
heterologous antigen 13. The endoplasmic reticulum
(ER) is where the major histocompatibility complex
(MHC) class I molecules are loaded with antigens.
Most of recombinant proteins are degraded in the
cytoplasm and few epitopes reach to the ER.
Theoretically, targeting of this anigens with an ER
retention signal (KDEL sequence) could induce
potent immune response 14.
In this study, cloning and expression and
purification of bFGF conjugated with
immunodominant domain of PE was done. For
increasing CTL response, the KDEL signal peptide
in triplicate was also used in designed coding
sequence. Fusion protein produced using
recombinant DNA technology in the bacterial
expression system. Software analysis and protein
expression analysis showed large scale production
of recombinant fusion protein.
MATERIALS AND METHODS
Designing the coding sequence and construction
of expression vector
The coding sequence of fusion protein
designed as a poly his-tag sequence at N-terminal
of fusion protein- the enterokinase cut site –coding
sequence of bFGF – rigid poly linker, (EAAAK) 4 -
coding sequence of domain 1b and 2 of PE and
(KDEL) 3 sequence. Finally, the NcoI and XhoI
restriction site were introduced at the two ends of
designed coding sequence. According to bacterial
expression system, using bioinformatics software
such as DNA2 and I-TASSER, the coding sequence
was optimized. Prediction of secondary structure
was assessed with online PSIPRED program (http:/
/bioinf.cs.ucl.ac.uk/psipred). Designed coding
sequence was purchased in the pUC57cloning
vector (shine gene).
Then, expression vectors (pET28a) and
cloning vector (pUC57) were digested by NcoI and
XhoI restriction enzymes. Linearized expression
vector and coding sequence extracted from agarose
gel utilizing miniprep kit (Qiagen). Ligation of coding
sequence into linearized expression vectors was
done by T4 DNA ligase. The colony PCR test using
forward and reverse T7-promoters and DNA
sequencing were used for confirmation the correct
insertion into the cloning site of expression vectors.
Recombinant protein expression and purification
The E. coli strains BL21 (DE3) was used
for protein expression. Designed expression vector
introduced into the BL21 bacterial using heat shock
at 42oC. The optimization of protein expression was
performed by monitoring the total protein
expression. Briefly, overnight cultures of transformed
bacteria were inoculated into 250 ml of LB broth
containing 30 ìg/ml of kanamycin. It incubated at
37oC with shaking at 130 rpm until the OD600
reached to 0.8. Expression of recombinant proteins
was induced with 1 mM IPTG and was monitored at
various incubation times (4, 8 and 16 hours). Total
protein were assessment by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE, 12%). For Western blot analysis, total
proteins were transferred to a nitrocellulose
membrane at 400 mA for 45 minute using an
electroblot system. Membranes were then washed
extensively with PBS buffer (0.15M, pH 7.4) and
blocked with 3% of skim milk. The membranes were
shacked for 1.5 hour at room temperature with anti-
bFGF monoclonal antibody (Abnova) at final dilution
of 1:500 in PBS buffer containing 3% of skim milk.
After stringent washing using PBS-tween- skim milk
solution (0.05% tween, 3% of skim milk), the
membranes were incubated with 1:1000 HRP
conjugated sheep anti mouse antibody (Sigma) for
1.5 hour. After washing the membranes,
recombinant protein was detected using DAB as
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the substrate for HRP and the appearance of brown
colored band on the membrane confirmed
recombinant protein expression 15. For purification
of recombinant fusion protein, the Ni NTA agarose
was used according to manufacture instruction
(Qiagen). The condition of our purification method
was reducing.
RESULTS AND DISCUSSION
Cancer immunotherapy is one the most
intrinsic aspect in cancer therapy 16. Utilization of
humoral and cellular immune elements is useful in
this strategy 17,18. In immunotherapy, more detailed
recognition of target (cancer cell) is necessary. The
process by which normal cells become malignant
is not well known, but the sequential of mutations
were seen in the genome of cancer cells. Although
tumor mass generate from a unique mutant cancer
cell, but cancer cells have different genotype and
phenotype 19. The best approach in recognition and
manipulation of cancer cells is selecting
immunogenic markers that have not mutations, over
expression in all cancer cells and not expressed in
normal cells, or have low expression 20.
New growth in the vascular network is
important for proliferation and metastasis of cancer
cells. Therefore, targeting of this process may be
useful in treatments of cancer patients 21.
Angiogenesis is regulated by activator molecules
such as VEGF and bFGF 3 , so anti-angiogeic
treatments may be useful in cancer therapy.
The bFGF has low immunogenicity and
short half-life in blood circulation, thus it cannot
stimulate an effective immune response 10.Thus,
increasing of its immunogenicity may be useful in
controlling of cancer cells. Domain 1b and 2 of the
PE is one of the potent antigenic carrier which could
significantly increase immunogenicity of low
immunogenic antigens 12.
In addition to increasing immunogenicity
of low immunogenic antigens , PE toxin was also
used for direct killing target cells such as cancer
cells. Gawlak et al expressed recombinant fusion
protein composed of bFGF and PE (toxin parts) that
contain domain II and III in bacterial expression
system. Recombinant fusion protein has
considerable activity on inhibition of different cancer
cell line22.
The first step in evaluation of new
designed protein is large scale production of it.
There are different approaches for production of
Fig.1: Agarose gel electrophoresis pattern of
the colony PCR product. The band close to
1200 bp band in Lanes A, B and D illustrates
successful insertion of desired coding
sequence into pET28a cloning site. Lane C is
negative control of PCR.
Fig . 2: Profile of protein expression in
transformed BL21 bacteria. Lane E is protein
expression in untransformed bacteria. Lane M
is molecular weight marker. Lanes B, C, and D
indicate protein expression at 16, 8, and 4
hours after induction, respectively. Lane A is
purified recombinant fusion protein using Ni-
affinity chromatography.
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designed proteins such as chemical synthesis and
using biological expression system 15,23. Since post-
translational modification of designed fusion protein
is not necessary for developing of linear epitops
and considerable part of designed fusion protein
has bacterial source (PE), bacterial expression
system was used for production of designed protein.
Moreover, bacterial expression provides an
economical method for production recombinant
proteins and requires minimal technical specialty
24
In bacterial expression system, the pET
Expression System is the best option for
production of recombinant proteins
The pET28 vector enables the quick
production of a large scale production of
recombinant protein 24. In this expression system,
the his tag sequences facilitate purification of target
protein and kanamycin resistance gene lead to easy
screening 25.
In this study, we tried to produce a new
fusion protein that consists of bFGF and
immunodominant part of PE (domain1b and 2) as
carrier protein. In designated coding sequence,
different part of recombinant fusion protein had logic
and specific location. His tag sequence introduce
at N-terminal for affinity chromatography 26 and the
KDEL sequence at C-terminal for high loading of
desired epitop in MHC class I grove and lead to
activation of CTL response against bFGF 27. For
avoidance of overlapping determinants, the rigid
poly linker with alpha helix structure was used
between to mentioned proteins 28. Bioinformatics
prediction of codon adaptation index (CAI) and GC
content showed that these parameters after
optimization reached to 0.83 (CAI) and 54.7% for
GC content. Prediction of secondary structure with
PSIPRED program verifies rigid linker can be formed
an alpha helix structure. After optimization and
synthesis, coding sequence subcloned into
expression vectors pET28. Investigation of colony
PCR by T7-promoter showed a clear band near to
1200 bp that has similar size with designed coding
sequence (Figure 1). Presentation and orientation
of different part of coding sequence were also
approved by DNA sequencing.
Prediction of three-dimensional structure
of fusion protein with I-TASSER software showed
that PE and bFGF are well separated from each
other with rigid poly linker and do not interact with
each other.
Expression of recombinant fusion protein
was induced with IPTG. Expression of recombinant
fusion protein was investigated by SDS-PAGE and
western blot analyses. Assessment of it in
transformed BL21 bacteria revealed a band close
to 38 kDa in SDS-PAGE that was aligned completely
to the expected recombinant protein (Figure 2).
Lane A in figure 2 also indicated purification of
recombinant protein was done perfectly. Figure 3
showed the result of western blot analysis. The band
approximately close to 38 kDa confirmed that
expressed protein is designed recombinant fusion
protein.
According to our knowledge, this study is
the first work that considered molecular cloning and
expression of bFGF conjugated with
immunodominant domain of PE (domain1b and 2)
using rigid linker in bacterial expression system.
Fig. 3: Western blot analysis of expressed
fusion protein using anti bFGF monoclonal
antibody. Lane M is Pre-stained molecular
Weight marker. Lanes A, B, and C are profile of
protein expression in BL21 bacteria
transformed with recombinant pET28a vector
after 16, 8, and 4 hours post transformation.
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